Current and future perspectives on clinical management of classic 21-hydroxylase deficiency
Optimizing the glucocorticoid dosage has been a major concern in classic 21OHD (21-hydroxylase deficiency) treatment, as it is essential to adjust it meticulously to the needs of the individual patient. Insufficient glucocorticoid treatment will cause adrenal insufficiency, including life-threatenin...
Saved in:
Main Authors: | Analia Yogi, Kenichi Kashimada |
---|---|
Format: | Article |
Language: | English |
Published: |
The Japan Endocrine Society
2023-10-01
|
Series: | Endocrine Journal |
Subjects: | |
Online Access: | https://www.jstage.jst.go.jp/article/endocrj/70/10/70_EJ23-0075/_html/-char/en |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Nationwide carrier screening for congenital adrenal hyperplasia: integrated approach of CYP21A2 pathogenic variant genotyping and comprehensive large gene deletion analysis
by: Yossawat Suwanlikit, et al.
Published: (2025-01-01) -
Development of a Hydrocortisone Orodispersible Thin Film Containing Its Succinate Prodrug
by: Clément Boisseillier, et al.
Published: (2025-01-01) -
Semaglutide and laparoscopic sleeve gastrectomy in an adolescent with congenital adrenal hyperplasia due to 21-hydroxylase: a case report
by: Alaina P. Vidmar, et al.
Published: (2025-01-01) -
High clinical utility of long-read sequencing for precise diagnosis of congenital adrenal hyperplasia in 322 probands
by: Yunpeng Wang, et al.
Published: (2025-01-01) -
The mutational landscape of ARMC5 in Primary Bilateral Macronodular Adrenal Hyperplasia: an update
by: Lucas Bouys, et al.
Published: (2025-02-01)